EYPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EyePoint Inc (EYPT) is not a strong buy for a beginner, long-term investor at this time. While analysts have raised price targets significantly and maintain a Buy rating, the company's financial performance shows severe revenue decline and weak gross margins. Additionally, technical indicators and options data suggest mixed signals, and there are no recent news or significant catalysts to drive immediate growth. Holding the stock may be a better strategy until clearer positive trends emerge.
The MACD is positive and expanding, indicating bullish momentum. However, RSI is neutral at 73.996, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level of 14.724, with limited upside potential in the short term.
Analysts have raised price targets significantly, with the highest target at $36, reflecting confidence in the company's future potential. The company's Phase 3 diabetic macular edema program has been included in valuations, indicating potential long-term growth.
The company's financials for Q4 2025 show a drastic revenue decline of -94.65% YoY and a significant drop in gross margin. No recent news or events suggest immediate growth catalysts. Stock trend analysis predicts a potential decline of -2.78% in the next week and -3.85% in the next month.
In Q4 2025, revenue dropped by -94.65% YoY to $620,000. Net income improved to -$67.61M, up 63.31% YoY, and EPS increased to -0.81, up 26.56% YoY. However, gross margin dropped significantly to 39.52%, down -57.49% YoY, indicating weak operational efficiency.
Analysts are bullish, with multiple firms raising price targets in March 2026. Citi raised the target to $35, H.C. Wainwright to $30, Chardan to $29, and Mizuho to $36. All firms maintain a Buy or Outperform rating, reflecting confidence in the stock's long-term potential.
